Kamada Ltd. (NASDAQ:KMDA) Sees Significant Growth in Short Interest

Kamada Ltd. (NASDAQ:KMDA) was the target of a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 166,100 shares, a growth of 2,002.5% from the January 31st total of 7,900 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average daily volume of 175,600 shares, the days-to-cover ratio is presently 0.9 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Kamada in a research note on Friday, January 10th.

Kamada Price Performance

KMDA traded down $0.08 during mid-day trading on Thursday, hitting $7.03. The stock had a trading volume of 36,703 shares, compared to its average volume of 277,864. The stock’s fifty day simple moving average is $6.99 and its 200-day simple moving average is $6.09. The firm has a market capitalization of $403.80 million, a price-to-earnings ratio of 25.14, a price-to-earnings-growth ratio of 0.97 and a beta of 0.99. Kamada has a 1-year low of $4.74 and a 1-year high of $9.15.

Institutional Investors Weigh In On Kamada

Hedge funds have recently bought and sold shares of the company. Plato Investment Management Ltd acquired a new stake in Kamada in the third quarter worth $117,000. Public Employees Retirement System of Ohio acquired a new stake in Kamada in the third quarter worth $77,000. JPMorgan Chase & Co. acquired a new stake in Kamada in the fourth quarter worth $67,000. Geode Capital Management LLC raised its holdings in Kamada by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 1,549 shares during the period. Finally, NewEdge Advisors LLC raised its holdings in shares of Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 8,260 shares during the period. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.